(NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance ...
Next generation continuous direct compression (CDC) platform, jointly developed with GEA, to bring a continuous tableting ...
Vasomune's lead therapy targeting vascular leak, for dual-use applications. TORONTO--(BUSINESS WIRE)--#ARDS--Vasomun ...
(“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the ...
All signs continue to point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin ...
VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ...
ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET. Orion Pharma announces first patient dosed in Phase 1/2 ...
New non-human primate data show Coave's ligand-conjugated suprachoroidal vector, coAAV-SCS, achieved up to 120-fold higher ...
In addition to the financing, Zenflow announced it has entered into an exclusive U.S. distribution agreement with Cook ...
Multi-year expansion of the companies’ 2025 agreement to use Gate’s Molecular Gate drug discovery engine to design molecular ...
Inducement Plan. Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious ...
Texas Ibogaine Research Corporation (“TIRC”), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results